Roth Capital analyst Jeff Martin lowered the firm’s price target on TransAct Technologies (TACT) to $5 from $6 and keeps a Buy rating on the shares. The firm notes that its prior thesis was based, in part, on a positive outcome from the strategic business review, which has now been suspended. FST and Casino & Gaming segments are performing well while the outlook for TransAct in 2025 remains breakeven to modestly negative on an adjusted EBITDA basis, the analyst tells investors in a research note.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TACT:
- TransAct Technologies Reports Strong Q1 2025 Results
- TransAct Technologies reports preliminary Q1 EPS 0c vs (10c) last year
- TransAct Technologies backs FY25 revenue view $47M-$52M, two estimates $47.93M
- TransAct Technologies suspends strategic review process ‘for now’
- TACT Earnings this Week: How Will it Perform?